| Market Cap | 6.84M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -41.05M | Forward P/E | -0.37 | EPS next Y | - | 50D Avg Chg | -45.00% |
| Sales | 7.33M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -79.00% |
| Dividend | N/A | Price/Book | 0.30 | EPS next 5Y | - | 52W High Chg | -95.00% |
| Recommedations | 2.00 | Quick Ratio | 0.24 | Shares Outstanding | 8.42M | 52W Low Chg | 38.00% |
| Insider Own | 69.72% | ROA | -26.24% | Shares Float | 3.46M | Beta | 1.14 |
| Inst Own | 2.00% | ROE | -98.69% | Shares Shorted/Prior | 130.76K/95.50K | Price | 0.81 |
| Gross Margin | -110.00% | Profit Margin | - | Avg. Volume | 83,461 | Target Price | - |
| Oper. Margin | -310.97% | Earnings Date | Nov 13 | Volume | 78,507 | Change | -0.26% |
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
